**Supplement 2**

**a. Study discontinuations**

|  |  |  |
| --- | --- | --- |
|  | **25 mg** | **5 mg** |
| Discontinuation | 61 (65%) | 74 (78%) |
| * due to progressive disease
 | 27 (29%) | 42 (45%) |
| * due to AE
 | 27 (29%) | 26 (28%) |
| * due to death
 | 3 (3%) | 1 (1%) |
| * due to refusal
 | 4 (4%) | 5 (5%) |
| Median time (range) until EOT [months] | 26.8 (0.5 – 87) | 22.9 (0.3 – 69) |

**b. Dose reductions**

|  |  |
| --- | --- |
| **Causes for dose reduction** | **N = 337** |
| Neutropenia | 187 (56) |
| Thrombocytopenia | 31 (9) |
| Constitutional symptoms | 24 (7) |
| Infection | 17 (5) |
| Dermatological AEs | 14 (4) |
| New primary malignancy | 13 (4) |
| Neurological AEs | 13 (4) |
| Patient request | 9 (3) |
| Anemia  | 9 (3) |
| Renal AEs | 6 (2) |
| GastrointestinaI + Liver AEs | 5 (2) |
| Death | 4 (1) |
| Pulmonal AEs | 3 (1) |
| Cardiac AEs | 2 (1) |
| Bleeding | 0 (0) |

**Abbreviations:** AE: adverse event, EOT: end of treatment

**c. Periods on and off study drug**

**Group A (25 mg)**



**Group B (5 mg)**



Blue bars show duration of remission on study drug, orange bars show duration of remission off study drug, X mark disease progression, bars ending without X = remission at last follow-up